title: Analysis of serious adverse events. Lipid-lowering therapy revisited.
authors.forename: Jim M
authors.initials: JM
authors.lastname: Wright
authors.forename: Lorri
authors.initials: L
authors.lastname: Puil
authors.forename: Carol Lee Ken
authors.initials: CL
authors.lastname: Bassett
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control; D002995:Clofibric Acid / Q000009:adverse effects; D015248:Gemfibrozil / Q000009:adverse effects; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000009:adverse effects; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D009026:Mortality; D018579:Patient Selection; D012306:Risk
chemical_list: D000960:Hypolipidemic Agents; D002995:Clofibric Acid; D006903:Hydroxymethylglutaryl CoA Reductases; D015248:Gemfibrozil